{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"TTNT is defined as the time from the date of first dose administration of any study drug to the date of the first dose initiation of the next line of anticancer therapy for any reason or death from any cause, whichever comes first. Participants who have not started the next-line therapy will be censored at the date last known to be alive before subsequent anticancer therapy.","groups":[{"description":"Participants were planned to receive modakafusp alfa at dose level 1 (DL1) \\[selected from Phase 1 Dose Escalation\\] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.","id":"OG000","title":"Phase 2a Dose Finding: Modakafusp Alfa (DL1) + Daratumumab"},{"description":"Participants were planned to receive modakafusp alfa at dose level 2 (DL2) \\[selected from Phase 1 Dose Escalation\\] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.","id":"OG001","title":"Phase 2a Dose Finding: Modakafusp Alfa (DL2) + Daratumumab"}],"populationDescription":"After completion of Phase 1 Dose Escalation of this study the sponsor decided not to proceed with Phase 2a due to strategic reasons (no safety concerns). Thus, no participants were enrolled for Phase 2a \\& no data was collected for this outcome measure due to study termination.","reportingStatus":"POSTED","timeFrame":"Phase 2a: Up to 15.9 months","title":"Phase 2a: Time to Next Treatment (TTNT)","type":"SECONDARY"}